Literature DB >> 27393347

Integrative analysis of diffusion-weighted MRI and genomic data to inform treatment of glioblastoma.

Guido H Jajamovich1, Chandni R Valiathan2, Razvan Cristescu3, Sangeetha Somayajula2.   

Abstract

Gene expression profiling from glioblastoma (GBM) patients enables characterization of cancer into subtypes that can be predictive of response to therapy. An integrative analysis of imaging and gene expression data can potentially be used to obtain novel biomarkers that are closely associated with the genetic subtype and gene signatures and thus provide a noninvasive approach to stratify GBM patients. In this retrospective study, we analyzed the expression of 12,042 genes for 558 patients from The Cancer Genome Atlas (TCGA). Among these patients, 50 patients had magnetic resonance imaging (MRI) studies including diffusion weighted (DW) MRI in The Cancer Imaging Archive (TCIA). We identified the contrast enhancing region of the tumors using the pre- and post-contrast T1-weighted MRI images and computed the apparent diffusion coefficient (ADC) histograms from the DW-MRI images. Using the gene expression data, we classified patients into four molecular subtypes, determined the number and composition of genes modules using the gap statistic, and computed gene signature scores. We used logistic regression to find significant predictors of GBM subtypes. We compared the predictors for different subtypes using Mann-Whitney U tests. We assessed detection power using area under the receiver operating characteristic (ROC) analysis. We computed Spearman correlations to determine the associations between ADC and each of the gene signatures. We performed gene enrichment analysis using Ingenuity Pathway Analysis (IPA). We adjusted all p values using the Benjamini and Hochberg method. The mean ADC was a significant predictor for the neural subtype. Neural tumors had a significantly lower mean ADC compared to non-neural tumors ([Formula: see text]), with mean ADC of [Formula: see text] and [Formula: see text] for neural and non-neural tumors, respectively. Mean ADC showed an area under the ROC of 0.75 for detecting neural tumors. We found eight gene modules in the GBM cohort. The mean ADC was significantly correlated with the gene signature related with dendritic cell maturation ([Formula: see text], [Formula: see text]). Mean ADC could be used as a biomarker of a gene signature associated with dendritic cell maturation and to assist in identifying patients with neural GBMs, known to be resistant to aggressive standard of care.

Entities:  

Keywords:  Apparent diffusion coefficient; Glioblastoma multiforme; Imaging genomics; Immunotherapy

Mesh:

Substances:

Year:  2016        PMID: 27393347     DOI: 10.1007/s11060-016-2174-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  71 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.

Authors:  Kuei C Lee; Bradford A Moffat; Anne F Schott; Rachel Layman; Steven Ellingworth; Rebecca Juliar; Amjad P Khan; Mark Helvie; Charles R Meyer; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

3.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

Review 4.  Imaging Genomics of Glioblastoma: Biology, Biomarkers, and Breakthroughs.

Authors:  Safwan Moton; Mohamed Elbanan; Pascal O Zinn; Rivka R Colen
Journal:  Top Magn Reson Imaging       Date:  2015-06

Review 5.  Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology.

Authors:  Mohamed G ElBanan; Ahmed M Amer; Pascal O Zinn; Rivka R Colen
Journal:  Neuroimaging Clin N Am       Date:  2015-02       Impact factor: 2.264

6.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

7.  Regulatory T cells are not a strong predictor of survival for patients with glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Gilbert J Rahme; Thomas H Hampton; Udo Baron; Sven Olek; Tim Schwachula; C Harker Rhodes; Jiang Gui; Laura J Tafe; Gregory J Tsongalis; Joel A Lefferts; Heather Wishart; Jonathan Kleen; Michael Miller; Chery A Whipple; Francine B de Abreu; Marc S Ernstoff; Camilo E Fadul
Journal:  Neuro Oncol       Date:  2015-01-24       Impact factor: 12.300

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

9.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.

Authors:  David A Gutman; Lee A D Cooper; Scott N Hwang; Chad A Holder; Jingjing Gao; Tarun D Aurora; William D Dunn; Lisa Scarpace; Tom Mikkelsen; Rajan Jain; Max Wintermark; Manal Jilwan; Prashant Raghavan; Erich Huang; Robert J Clifford; Pattanasak Mongkolwat; Vladimir Kleper; John Freymann; Justin Kirby; Pascal O Zinn; Carlos S Moreno; Carl Jaffe; Rivka Colen; Daniel L Rubin; Joel Saltz; Adam Flanders; Daniel J Brat
Journal:  Radiology       Date:  2013-02-07       Impact factor: 11.105

10.  Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.

Authors:  Zhe Zhang; Haihui Jiang; Xuzhu Chen; Jiwei Bai; Yong Cui; Xiaohui Ren; Xiaolin Chen; Junmei Wang; Wei Zeng; Song Lin
Journal:  J Neurooncol       Date:  2014-05-15       Impact factor: 4.130

View more
  4 in total

1.  BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients.

Authors:  Hye Rim Cho; Hyejin Jeon; Chul-Kee Park; Sung-Hye Park; Koung Mi Kang; Seung Hong Choi
Journal:  Sci Rep       Date:  2017-12-18       Impact factor: 4.379

Review 2.  Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis.

Authors:  Robin W Jansen; Paul van Amstel; Roland M Martens; Irsan E Kooi; Pieter Wesseling; Adrianus J de Langen; Catharina W Menke-Van der Houven van Oordt; Bernard H E Jansen; Annette C Moll; Josephine C Dorsman; Jonas A Castelijns; Pim de Graaf; Marcus C de Jong
Journal:  Oncotarget       Date:  2018-04-13

3.  Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging.

Authors:  Stefanie J Hectors; Mathilde Wagner; Octavia Bane; Cecilia Besa; Sara Lewis; Romain Remark; Nelson Chen; M Isabel Fiel; Hongfa Zhu; Sacha Gnjatic; Miriam Merad; Yujin Hoshida; Bachir Taouli
Journal:  Sci Rep       Date:  2017-05-26       Impact factor: 4.996

Review 4.  Radiomic biomarkers of tumor immune biology and immunotherapy response.

Authors:  Jarey H Wang; Kareem A Wahid; Lisanne V van Dijk; Keyvan Farahani; Reid F Thompson; Clifton David Fuller
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.